In patients with compromised immune function, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (CoVID-19) impose particular challenges. Especially in hematological malignancies, including lymphoma, the demands by this novel virus disease are further enhanced during sophisticated treatments, such as chimeric antigen receptor (CAR) T-cell therapy. Here, we present the first case of a patient with refractory diffuse-large B-cell lymphoma, who underwent CAR T-cell treatment in the context of SARS-CoV-2. Irrespective of prolonged and active SARS-CoV-2 infection, T cells were successfully isolated by apheresis and processed to anti-CD19 CAR T cells (axicabtagene-ciloleucel). In light of the aggressive lymphoma course, lymphodepleting chemotherapy and CAR-T cells were administered in early recovery after oxygen-dependent CoVID-19 pneumonia. Except for moderate cytokine release, this cellular immunotherapy was well tolerated. Notably, there is no deterioration of the SARS-CoV-2 infection; however, complete lymphoma response and full clinical recovery were observed. In conclusion, CAR T-cell treatment in aggressive lymphoma in the setting of SARS-CoV-2 infection is feasible and may offer significant therapeutic activity in refractory disease.
【저자키워드】 COVID-19, SARS-CoV-2, Pneumonia, diffuse large B-cell lymphoma, Chimeric antigen receptor T-cells, 【초록키워드】 Treatment, coronavirus disease, coronavirus, therapy, Hematological malignancies, Immunotherapy, SARS-COV-2 infection, Infection, Chemotherapy, clinical recovery, T cell, Deterioration, B-cell lymphoma, lymphoma, Patient, immune function, T-cell, disease, moderate, chimeric antigen receptor, cellular, Virus Disease, early recovery, acute respiratory syndrome, cytokine release, therapeutic activity, offer, Administered, Complete, CAR, Anti-CD19, Course, feasible, processed, CAR-T cell, the SARS-CoV-2, 【제목키워드】 coronavirus 2, respiratory, Prolonged, report, CAR, Aggressive,